Bright Peak Therapeutics

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

Website

https://www.brightpeaktx.com/

Externer Link zu Bright Peak Therapeutics

Branche

Biotechnologieforschung

Größe

51–200 Beschäftigte

Hauptsitz

Basel

Art

Privatunternehmen

Gegründet

2017